|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:naloxone
gptkb:buprenorphine
|
|
gptkbp:approvedBy
|
gptkb:FDA
2002
|
|
gptkbp:ATCCode
|
N07BC51
|
|
gptkbp:availableOn
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:brand
|
buprenorphine/naloxone
|
|
gptkbp:contraindication
|
severe respiratory depression
hypersensitivity to buprenorphine or naloxone
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_III_(US)
|
|
gptkbp:drugClass
|
combination drug
opioid
opioid partial agonist
|
|
gptkbp:eliminationHalfLife
|
2-12 hours (naloxone)
24-42 hours (buprenorphine)
|
|
gptkbp:form
|
gptkb:film
gptkb:tablet
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Suboxone
|
|
gptkbp:indication
|
detoxification of opioid dependence
maintenance treatment of opioid dependence
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:benzodiazepines
other CNS depressants
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
Indivior
|
|
gptkbp:marketedAs
|
Indivior
Reckitt Benckiser (formerly)
|
|
gptkbp:mechanismOfAction
|
opioid
partial opioid agonist
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
physicians with special waiver (US)
|
|
gptkbp:riskFactor
|
hepatitis
respiratory depression
abuse potential
precipitated withdrawal
|
|
gptkbp:routeOfAdministration
|
sublingual
buccal
|
|
gptkbp:sideEffect
|
nausea
constipation
headache
sweating
insomnia
withdrawal symptoms
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:usedFor
|
opioid dependence
|
|
gptkbp:bfsParent
|
gptkb:Buprenorphine
gptkb:buprenorphine
|
|
gptkbp:bfsLayer
|
6
|